Idiopathic sudden sensorineural hearing loss... (2023 study) Skip to main content
Retrospective Study Frontiers in neurology 2023

Idiopathic sudden sensorineural hearing loss: effectiveness of salvage treatment with intratympanic dexamethasone or hyperbaric oxygen therapy in addition to systemic steroids.

Mariani C, Carta F, Catani G, Lobina S, Marrosu V, Corrias S, et al., Frontiers in neurology, 2023

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers looked back at records from patients whose sudden hearing loss had not fully improved after standard steroid treatment, to see how adding intratympanic steroid injections or hyperbaric oxygen therapy affected their hearing recovery.

What They Found

This retrospective study followed 62 patients who had not recovered after initial systemic steroid treatment and were split into three groups: steroids alone (34 patients, 54.8%), steroids plus hyperbaric oxygen therapy (16 patients, 25.8%), and steroids plus intratympanic steroids (12 patients, 19.4%). The proportion of patients who responded to treatment was actually higher in the steroids-alone group (29.4%) than in the hyperbaric oxygen group (18.75%) or the intratympanic steroid group (16.7%). The study found no statistically significant difference between the three groups in average hearing gain measured three months after the salvage treatment began.

What This Means for Canadian Patients

For patients whose hearing loss does not improve with initial steroid treatment, this study did not find that adding hyperbaric oxygen therapy or intratympanic steroids produced a statistically meaningful improvement in hearing gain compared to continuing steroids alone. The response rate was numerically lower in the groups that received these salvage treatments. Patients considering salvage options for sudden hearing loss should discuss this evidence gap with their treating physician.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

This was a retrospective, non-randomized study with small and unequal group sizes (12 to 34 patients per group) from a single hospital, which limits the ability to draw firm conclusions about the effectiveness of either salvage treatment.

This plain-language summary was generated with AI assistance from the study's abstract; it has not been individually reviewed by a clinician. Always consult the source study and a qualified healthcare professional. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Retrospective Study
Category Sudden Hearing Loss
Source Pubmed
PubMed ID 37693762
Year Published 2023
Journal Frontiers in neurology

Cite This Study

Share

This study relates to Sudden Sensorineural Hearing Loss. Read the full clinical overview, the evidence base, and Canadian treatment access for this condition.

Find a Canadian Clinic Treating Sudden Hearing Loss

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last updated: April 1, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology